VolitionRX Ltd
VNRXAMEXHealthcareMedical - Devices
Previous close
$0.4169
−$0.0275 · -6.19%
Pre-market
$0.4192
+$0.0023 · +0.55%
Aug 24, 4:09 AM ET
VNRX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
57
Fair Value
Momentum
21
Weakening
Sentiment
51
Mixed
Risk resilience
27
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteVolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Cameron Reynolds
- Listed since
- Mar 2, 2012
- Employees
- 57
Market position
Day range
Current $0.4169
52-week range
Current $0.4169
- Open
- $0.44
- Previous close
- $0.4444
- Volume
- 538.13K
- 1.18× average
- Average volume
- 455.25K
- Average daily volume
- Market cap
- 3.48M USD
- Beta
- 1.14
- Market reference 1
- 50-day average
- $1.0426
- -60.01% below average
- 200-day average
- $3.6179
- -88.48% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 37.64M USD
- EV / EBITDA
- -1.9×
- Earnings yield
- -85.57%
- Free cash flow yield
- -72.44%
Profitability & efficiency
- Return on equity
- 68.20%
- Return on assets
- -338.45%
- Return on invested capital
- 1236.74%
Financial health
- Current ratio
- 0.17×
- Altman Z-score
- -53.11
- Piotroski F-score
- 3 of 9
Earnings
- EPS beat rate
- 0%
- 0 beats, 9 misses, 2 met estimates
- Average EPS surprise
- -172.43%
- 11 comparable reports
- Latest EPS result
- -0.85
- Estimate -0.57 · Miss by 49.78%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
VNRX news
VNRX peers
ETFs holding VNRX
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research VNRXresearch.disclaimer